drugset / Trial / NCT02623465

A Study of a New Type of Insulin in Participants With Type 2 Diabetes on Insulin Injection Therapy

NCT02623465

Phase 1 Withdrawn Eli Lilly and Company
RandomizedCrossoverDouble-blindBasic science

Summary

The study will be conducted in participants with type 2 diabetes on insulin injection therapy to investigate how the body processes a test formulation of insulin lispro and the effect of the test formulation on blood sugar levels. Side effects and tolerability will be documented. The study will be conducted in two parts (Part A and Part B) to achieve its objectives. Participants are expected to enroll in both parts.

Timeline

Start
2018-01
Primary completion
2018-04
Completion
2018-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin Lispro Protein / enzyme biologic Subcutaneous